Visa’s $425 Target Depends on Services Outrunning Core Payments

Visa’s higher analyst target leans on value-added services and stable spending, while the October 27 earnings report will test whether that growth offsets mature payment volumes.
Visa’s latest bullish call is built on businesses that sit around the card swipe, not only on the swipe itself. BMO raised its price target from $405 to $425 and kept an Outperform rating, citing stable consumer spending and expectations that value-added services can grow in the high-20% range.
Those services include fraud tools, consulting, data products and issuing support. They matter because they can grow faster than core payment volumes and deepen relationships with banks and merchants. Visa is also expanding Visa Direct, including a stablecoin prefunding pilot with Inyo, but a pilot is evidence of experimentation rather than proof of material revenue.
Visa is scheduled to report fiscal fourth-quarter and full-year 2026 results on October 27. The source report cited consensus estimates of $12.18 billion in revenue and $3.42 of earnings per share. The useful comparison will be between payments volume, cross-border growth and the pace of value-added services, rather than the headline beat alone.
The $425 target assumes resilient spending and continued execution. A consumer slowdown would pressure transaction growth, while regulatory changes could affect fees. Faster services growth would help cushion both risks, but investors should distinguish an analyst forecast from company guidance.
Visa’s network still benefits from scale and recurring transaction activity. The next report must show that its adjacent services are becoming a second growth engine rather than simply a promising supplement to the core network.
Related News
Bank OZK's Rising Dividend Is Well Covered, but Credit Still Sets the Limit
Bank OZK raised its quarterly dividend for a 65th straight quarter. A payout near one-third of earnings provides room, while construction-loan credit remains the main constraint.
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Parabilis Heads Into ESMO With Strong Early Data and a High Bar
Parabilis will present updated zolucatetide data in desmoid tumors on Oct. 24. Early responses were strong, but investors still need durability, safety and a credible Phase 3 dose.
Pfizer's 5.8% Yield Depends on Cash Flow Catching Up
Pfizer's dividend remains covered by adjusted earnings, but 2025 free cash flow fell short of distributions. Debt and patent expirations leave management less room to restore dividend growth.
Three Stocks Hit New Lows, but the Risks Were Very Different
EyePoint, CoreWeave and Eos Energy touched new lows on the same day. The selloffs reflected three distinct problems: a failed pivotal trial, financing pressure and manufacturing execution risk.















Latest comments